Browsing by Author "Sloan, Caroline E"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
Item Open Access Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity.(Current atherosclerosis reports, 2023-12) Amin, Krunal; Bethel, Garrett; Jackson, Larry R; Essien, Utibe R; Sloan, Caroline EPurpose of review
Pharmacoequity refers to the goal of ensuring that all patients have access to high-quality medications, regardless of their race, ethnicity, gender, or other characteristics. The goal of this article is to review current evidence on disparities in access to cardiovascular drug therapies across sociodemographic subgroups, with a focus on heart failure, atrial fibrillation, and dyslipidemia.Recent findings
Considerable and consistent disparities to life-prolonging heart failure, atrial fibrillation, and dyslipidemia medications exist in clinical trial representation, access to specialist care, prescription of guideline-based therapy, drug affordability, and pharmacy accessibility across racial, ethnic, gender, and other sociodemographic subgroups. Researchers, health systems, and policy makers can take steps to improve pharmacoequity by diversifying clinical trial enrollment, increasing access to inpatient and outpatient cardiology care, nudging clinicians to increase prescription of guideline-directed medical therapy, and pursuing system-level reforms to improve drug access and affordability.Item Open Access Online Crowdfunding Campaigns for Diabetes-Related Expenses.(Annals of internal medicine, 2023-07) Sloan, Caroline E; Campagna, Ada; Tu, Karissa; Doerstling, Steven; Davis, J Kelly; Ubel, Peter ABackground: More than 40% of patients with diabetes in the United States have trouble paying their medical bills. Among patients with health-related financial hardship, 56% have delayed or foregone care (1). By one estimate, an insulin-dependent patient with insurance spends about $4800 annually on medications, physicians’ visits, supplies, hospitalizations, and lost wages, equivalent to 15% of the median U.S. per capita income (2). Crowdfunding is increasingly being used by patients struggling with medical costs (3). Crowdfunding campaigns can shed light on the types of expenses that patients with diabetes may struggle to afford (3). Objective: To leverage the rich real-world testimonies available in crowdfunding campaigns in order to characterize the financial challenges of patients with diabetes who seek fundraising support. Methods and Findings: We scraped a random sample of 89 645 active U.S. medical crowdfunding campaigns posted on GoFundMe from 2010 to August 2020, using a previously published natural-language algorithm (4). Campaigns were included if they were in English and requested money for a single person whose primary condition was diabetes. We randomly selected 350 of 807 campaigns that met inclusion criteria, with oversampling of type 1 diabetes campaigns to obtain roughly equal proportions of type 1 and non–type 1 diabetes campaigns and ensure a wide breadth of experiences. Campaigns described patients’ medical situations, expenses, and fundraising goals. We conducted a directed content analysis to evaluate for the presence of predetermined fundraising request categories (Table 1). Two authors double-coded the first 100 campaigns and 10% of the remaining 250 campaigns. Intercoder reliability using the Cohen κ coefficient was 0.67 or higher for all coding categories and direct medical expense subcategories. After exclusions, our final sample included 313 campaigns; 89% were posted during 2015 to 2020. The median fundraising goal was $10 000 (IQR, $4500 to $15 000), the median fundraising amount was $2600 (IQR, $1670 to $4760), and 14% of campaigns reached their goal. Table 2 highlights campaign characteristics overall and by stated diabetes type. One quarter of fundraisers reported having insurance; of these, 49% said their insurance covered their medical expenses but out-of-pocket costs were still too high. Almost half of direct medical expenses were not directly related to glucose control (99 of 206 [48%]). Only 6% requested money specifically for insulin. One fifth of campaigns (21%) requested money for diabetic alert dogs; almost all were campaigns for type 1 diabetes. Indirect medical expenses included lost wages, healthy food, moving to a new city to be closer to state-of-the-art medical care, car repairs to enable transportation to physicians’ appointments, personal trainers, home modifications to support new physical disabilities, and funeral expenses. Campaigns that were not specifically for type 1 diabetes (type 2 or unspecified) mentioned indirect medical expenses more often than campaigns for type 1 diabetes (63% vs. 34%). Discussion: Crowdfunding campaigns provide a window into the wide range of financial struggles that patients with diabetes may face. First, many aspects of diabetes care beyond insulin can be cost-prohibitive, including indirect expenses that clinicians may not be equipped to address. Although the Inflation Reduction Act’s cap on out-of-pocket costs for insulin is an important step in making care more affordable, policymakers should address other diabetes-related costs as well. Second, even people who have insurance use crowdfunding due to lack of coverage for certain expenses or unaffordable copayments. Third, 35% of patients with type 1 diabetes started fundraising campaigns for diabetic alert dogs, which cost about $15 000 and are not covered by insurance because of high variability in effectiveness (5). Clinicians who learn of a patient’s intent to purchase a dog could redirect them toward proven management strategies, such as continuous glucose monitors. Our conclusions are not generalizable to financially distressed patients who may not seek crowdfunding because of older age (people who use crowdfunding are generally younger [3]), poor internet access, or other reasons. Our use of content analysis limited our ability to consider textual context. We could not evaluate for fraud or consider patients’ reported versus actual financial needs. The expenses for which patients use crowdfunding include life-sustaining expenses, such as food and hospitalizations; unproven therapies, such as diabetic alert dogs; and less essential indirect costs, such as personal trainers. Future research should evaluate whether and how these expenses contribute to financial distress in the larger population of patients with diabetes, including those who do not use crowdfunding.Item Open Access Patients want to talk about their out-of-pocket costs-Can real-time benefit tools help?(Journal of the American Geriatrics Society, 2023-05) Sloan, Caroline E; Ubel, Peter AThis editorial comments on the article by Mattingly et al.Item Open Access Real-world use of a medication out-of-pocket cost estimator in primary care one year after Medicare regulation.(Journal of the American Geriatrics Society, 2024-01) Sloan, Caroline E; Morton-Oswald, Sarah; Smith, Valerie A; Sinaiko, Anna D; Bowling, C Barrett; An, Jaejin; Maciejewski, Matthew LItem Open Access Trends in Dialysis Industry Consolidation After Medicare Payment Reform, 2006-2016.(JAMA health forum, 2021-11) Sloan, Caroline E; Hoffman, Abby; Maciejewski, Matthew L; Coffman, Cynthia J; Trogdon, Justin G; Wang, VirginiaImportance
The dialysis industry is highly concentrated, with large dialysis organizations now providing dialysis for more than 85% of patients with kidney failure in the United States. In 2011, Medicare introduced a new Prospective Payment System (PPS) for end-stage kidney disease, which bundled payment for dialysis care into 1 payment per patient. Trends in dialysis facility consolidation after the PPS went into effect are unknown.Objective
To determine whether the introduction of the PPS in 2011 was associated with an acceleration in acquisitions and closures of small dialysis chains (<20 facilities) and independently owned facilities.Design setting and participants
This retrospective cohort study included all Medicare-certified independent or small chain-affiliated dialysis facilities in the continental US between 2006 and 2016. Data were obtained from Medicare and the US Renal Data System and were analyzed in 2020.Exposures
The PPS.Main outcomes and measures
Discrete time hazard models were used to estimate the odds of acquisition and closure before the PPS (2006-2010) vs after the PPS (2011-2016). Analyses controlled for facility, market, and regional demographic characteristics. The average predicted marginal probabilities of acquisition and closure over time were estimated.Results
The proportion of small chain-affiliated and independently owned facilities declined from 29% (1383 of 4750 facilities) in 2006 to 15% (1038 of 6738) in 2016. Among 13 481 facility-years, 6352 (47%) were for profit, and mean (SD) census was 68 (59) patients. Overall, 3286 (24%) facilities opened during the observation period. The proportion of acquisitions that occurred each year varied from 1.1% (12 of 1065 facilities in 2015) to 7.2% (86 of 1192 facilities in 2012), while closures varied from 0.8% (9 of 1065 facilities in 2015) to 2.2% (28 of 1286 facilities in 2010), making both fairly rare. There was a 3.48 higher odds of acquisition in the post-PPS period compared with the pre-PPS period (95% CI, 1.62-7.47; P = .001). The odds of closure before and after the PPS were not statistically significantly different (odds ratio, 2.03; 95% CI, 0.61-6.73; P = .25). Facilities that opened during the observation period had a 7.2% higher predicted probability of acquisition compared with older facilities (95% CI, 5.4%-9.0%; P < .001).Conclusions and relevance
In this cohort study of continental US Medicare-certified dialysis facilities, small-chain and independently owned facilities retained a declining share of the dialysis market. Further research should evaluate the effect of continued dialysis market consolidation on patient access, health care utilization, and clinical outcomes.